Eli Lilly announced impressive second-quarter 2025 financial results, with worldwide revenue reaching $15.56 billion, a substantial 38% increase compared to Q2 2024. This growth was primarily fueled by significant volume increases in its key medicines, Zepbound and Mounjaro. U.S. revenue alone surged 38% to $10.81 billion, largely due to a 46% increase in volume, despite an 8% decrease from lower realized prices.
The company's reported diluted earnings per share (EPS) for Q2 2025 rose by 92% to $6.29, while non-GAAP EPS increased by 61% to $6.31, both including $0.14 of acquired IPR&D charges. Following these strong results, Eli Lilly raised its full-year 2025 revenue guidance by $1.5 billion at the midpoint, now expecting revenue to be in the range of $60 billion to $62 billion. Reported EPS guidance was also raised to a range of $20.85 to $22.10, and non-GAAP EPS guidance to $21.75 to $23.00.
Key product revenue, led by Zepbound and Mounjaro, grew to $10.40 billion in Q2 2025. David A. Ricks, Lilly chair and CEO, highlighted the strong performance and continued advancement of their pipeline, including positive study results for orforglipron in obesity and Mounjaro's cardio-protective effects in type 2 diabetes and heart disease. The company also expanded manufacturing capacity to meet increasing demand.
